97 results about "Ketone concentration" patented technology

A compound which is 3-hydroxybutyl 3-hydroxybutyrate enantiomerically enriched with respect to (3R)-hydroxybutyl (3R)-hydroxybutyrate of formula (I) is an effective and palatable precursor to the ketone body (3R)-hydroxybutyrate and may therefore be used to treat a condition which is caused by, exacerbated by or associated with elevated plasma levels of free fatty acids in a human or animal subject, for instance a condition where weight loss or weight gain is implicated, or to promote alertness or improve cognitive function, or to treat, prevent or reduce the effects of neurodegeneration, free radical toxicity, hypoxic conditions or hyperglycaemia.

This invention relates to the field of therapeutic agents for the treatment of Age-Associated Memory Impairment (AAMI). In particular, the present invention utilizes compositions comprising at least one compound capable of elevating ketone body concentrations in a mammal (e.g., ketogenic compounds), administered in an amount effective for treatment or prevention of loss of cognitive function caused by reduced neuronal metabolism in AAMI. In one embodiment, the composition includes medium chain triglycerides (MCT). In another embodiment, the compositions are administered in the presence of carbohydrate. The present invention also relates to oral dosage forms, in particular, a nutritional drink comprising at least one compound capable of elevating ketone body concentrations in a mammal.

A compound which is 3-hydroxybutyl 3-hydroxybutyrate enantiomerically enriched with respect to (3R)-hydroxybutyl (3R)-hydroxybutyrate of formula (I) is an effective and palatable precursor to the ketone body (3R)-hydroxybutyrate and may therefore be used to treat a condition which is caused by, exacerbated by or associated with elevated plasma levels of free fatty acids in a human or animal subject, for instance a condition where weight loss or weight gain is implicated, or to promote alertness or improve cognitive function, or to treat, prevent or reduce the effects of neurodegeneration, free radical toxicity, hypoxic conditions or hyperglycaemia.

The subject disclosure provides compositions for reducing serum cholesterol and / or triglyceride levels in subjects. These compositions can comprise racemic β-hydroxybutyrate or D-β-hydroxybutyrate, optionally in the acid form, physiologically compatible salts of racemic β-hydroxybutyrate or D-β-hydroxybutyrate, esters of D-β-hydroxybutyrate, oligomers of D-β-hydroxybutyrate containing from 2 to 20 or more monomeric units in either linear or cyclic form, racemic 1,3 butandiol or R-1,3 butandiol alone and can be, optionally, administered in conjunction with a low fat diet to a subject. Alternatively, compositions comprising racemic β-hydroxybutyrate or D-β-hydroxybutyrate, optionally in the acid form, physiologically compatible salts of racemic β-hydroxybutyrate or D-β-hydroxybutyrate, esters of D-β-hydroxybutyrate, oligomers of D-β-hydroxybutyrate containing from 2 to 20 or more monomeric units in either linear or cyclic form, racemic 1,3 butandiol, R-1,3 butandiol or combinations thereof can be formulated as nutritional supplements (also referred to as nutritional compositions) or incorporated into therapeutic compositions containing a) anti-hypertensive agents; b) anti-inflammatory agents; c) glucose lowering agents; or d) anti-lipemic agents) which are administered to a subject, optionally in combination with a low fat diet, in order to cause a reduction or lowering of: serum cholesterol levels; triglyceride levels; serum glucose levels, serum homocysteine levels, inflammatory proteins (e.g., C reactive protein) and / or hypertension in treated subjects. Alternatively, compositions disclosed herein can be administered alone, or in combination with other therapeutic agents to prevent or reverse vascular disease.

A sensing device having a first and second opening, a first semipermeable membrane having a first surface and a second surface, and a second semipermeable membrane having a third and fourth surface, a ketone body sensor, and a void. The first opening is juxtaposed to the first surface and the second opening is juxtaposed to the third surface. The space between the first and second openings is the void and wherein the ketone body sensor is positioned within the void. Gasses may permeate through the first opening and into the void to contact the sensor and exit the void through the second opening.

Ketoacidosis is an extreme and uncontrolled form of ketosis, which is a normal response to prolonged fasting. Embodiments of this invention test the ketone level of a patient by measuring the ketone bodies in breath condensation. Some embodiments include a device for medical testing comprising a hollow container, comprising powder mixture of sodium nitroferricyanide, ammonium sulfate and silica and a liquid including an ammonium hydroxide solution.

Disposable test strips and a wet chemistry method for measuring each of beta-hydroxybutyrate alone, combined beta-hydroxybutyrate and acetoacetate or total ketone bodies (i.e., beta-hydroxybutyrate, acetoacetate and acetone) in human bodily fluid samples, including but not limited to urine, saliva or sweat are described. The test strips need only be dipped in the sample and can be used by anyone in almost any milieu. Measurement can be made electrochemically, spectrophotometrically, fluorometrically or by comparision to a color standard. Combined acetoacetate and beta-hydroxybutyrate which account for 97-98% of total ketone bodies and may be measured in a cyclic reaction that occurs at pH about 7.0 to about 8.3 with beta-hydroxybutyrate dehydrogenase, (beta-HBD), nicotinamide adenine dinucleotide, a tetrazolium dye precursor and an electron mediator. Using this reaction, false positive results obtained from urine samples taken from patients on sulfhydryl drugs are avoided. beta-HBD from some sources was found to cause false negative results in samples (e.g. urine) containing high chloride content due to chloride inhibition of beta-HBD. Using a simple test for chloride inhibition, it was found that beta-HBD from Alcaligenes is not so inhibited. Using either beta-HBD that is not inhibited by chloride or using 10-20 times the normal concentration of this enzyme eliminates false negatives in samples having substantial chloride content, such as urine, both in the reaction described above and in other reactions disclosed for measuring each of beta-hydroxybutyrate alone, combined beta-hydroxybutyrate and acetoacetate and total ketone bodies, all of which reactions occur in the pH range of about 8.6 to about 9.5.

Ketogenic compositions including a non-racemic mixture of beta-hydroxybutyrate (BHB) enriched with the S-enantiomer are formulated to control ketone body levels in a subject. The non-racemic mixture of BHB is enriched with the S-enantiomer to modulate the effect of ketone bodies in the subject and control the rate at which ketosis is achieved. In some aspects a composition for controlling ketone body level in a subject contains a dietetically or pharmaceutically acceptable carrier and a non-racemic mixture of S-beta-hydroxybutyrate and R-beta-hydroxybutyrate, wherein the non-racemic mixture contains from about 52% to 99% by enantiomeric equivalents of S-beta-hydroxybutyrate enantiomer and from about 48% to about 1% by enantiomeric equivalents of R-beta-hydroxybutyrate enantiomer.

Ketoacidosis is a medical emergency that requires swift intervention to avert life-threatening sequel. A body-worn sensor (50) configured to measure the levels of a ketone compound circulating in a physiological fluid of a wearer and capable of generating an alert to the wearer if the level of the circulating ketone compound exceeds a pre-defined level or rate of change is disclosed herein. The sensor (50) preferably includes at least one of an electrochemical sensor, an optical sensor, a galvanic sensor, a voltammetric sensor, an amperometric sensor, a potentiometric sensor, an impedimetric sensor, a resistive sensor, a capacitive sensor, an ultrasonic sensor, a radio-frequency sensor, or a microwave sensor.

Ketogenic compositions including a non-racemic mixture of beta-hydroxybutyrate (BHB) enriched with the R-enantiomer are formulated to increase ketone body level in a subject. The non-racemic mixture of BHB is enriched with the R-enantiomer to elevate ketone bodies and increase the rate at which ketosis is achieved yet contains an amount of the S-enantiomer sufficient to provide alternative benefits as discussed herein. In some aspects a composition for increasing ketone body level in a subject contains a dietetically or pharmaceutically acceptable carrier and a non-racemic mixture of R-beta-hydroxybutyrate and S-beta-hydroxybutyrate, wherein the non-racemic mixture of R-beta-hydroxybutyrate and S-beta-hydroxybutyrate contains from about 55% to 98% by enantiomeric equivalents of the R-beta-hydroxybutyrate and from about 45% to about 2% by enantiomeric equivalents of S-beta-hydroxybutyrate enantiomer.

The invention provides feed for improving ketone body quality of broilers. The feed comprises a main feed component, galactomannan, betaine, chromium nicotinate, soya bean lecithin, bee pollen, bone meal, sodium bicarbonate, lucerne meal, an amino acid additive, a vitamin additive, a traditional Chinese medicine feed additive for improving the ketone body quality and flavor of the broilers, and a microbe preparation. The traditional Chinese medicine feed additive and the feed for improving the ketone body quality and flavor of the broilers, which are provided by the invention, have the effects of low toxicity, no side effect and no residue, and can significantly improve the ketone body quality and flavor of the broilers.

Ketogenic compositions including a non-racemic mixture of beta-hydroxybutyrate (BHB) enriched with the R-enantiomer are formulated to increase ketone body level in a subject. The non-racemic mixture of BHB is enriched with the R-enantiomer to elevate ketone bodies and increase the rate at which ketosis is achieved yet contains an amount of the S-enantiomer sufficient to provide alternative benefits as discussed herein. In some aspects a composition for increasing ketone body level in a subject contains a dietetically or pharmaceutically acceptable carrier and a non-racemic mixture of R-beta-hydroxybutyrate and S-beta-hydroxybutyrate, wherein the non-racemic mixture of R-beta-hydroxybutyrate and S-beta-hydroxybutyrate contains from about 51% to 99.5% by enantiomeric equivalents of the R-beta-hydroxybutyrate and from about 49% to about 0.5% by enantiomeric equivalents of S-beta-hydroxybutyrate enantiomer.

The invention provides a physical change evaluation device, method, and program capable of easily evaluating physical change from the past to the present, and from the present into the future.A physical change evaluation device 10 acquires a ketone concentration measurement measuring ketone excreted from a user, acquires physical data relating to the body of the user, evaluates physical change in the user based on the acquired ketone concentration measurement and the physical data, and outputs an evaluation result.

The invention provides an analyte monitoring and automatic drug administrating system. The system comprises a detection unit, a processing unit, a calculation unit, an injection unit and a control unit. The detection unit comprises at least two detection parts, and each detection part is used for detecting an analysis object in analyte. The injection unit injects drugs according to the total drug injection amount calculated through the calculation unit, the injection unit comprises at least two injection parts, and each injection part is used for injecting the drugs. The control unit controls the detection unit, the processing unit, the calculation unit and the injection unit. According to the analyte monitoring and automatic drug administrating system, the concentration of the analyte (such as glucose or oxygen or triglyceride or ketone bodies) can be precisely monitored through a simple device, medicine injection is carried out by the injection parts at the same time, the medicine injection area can be effectively increased, skin induration can be obviously relieved, the medicine absorption effect can be effectively enhanced, and the treatment effect is improved.

The invention discloses a handheld type multi-parameter on-site fast biochemical detector, which relates to the technology of human body detection and comprises a multi-channel detecting circuit, a work voltage generating circuit, a power circuit, a bluetooth module, a display module, a single chip microprogrammed control unit (MCU), a fixing part embedded in a single chip and various detecting strips matched with the fixing part for use. The detector can automatically identify various detecting strips to achieve the following functions: 1 simultaneous detection of three parameters of blood sugar, blood lactic acid and a blood ketone body; 2 simultaneous detection of any two of the parameters; and 3 detection of any one parameter. The detector can automatically and fast finish detection and output detection results. The bluetooth module is built in the detector and can automatically send the detection results in wireless mode. The simultaneous detection of the three parameters can effectively reduce bleeding amount and suffering of a testee. Simultaneously, the multi-parameter biochemical detector further has the advantages of automatic and fast detection, convenience in carry, long standby time, wireless data transmission and the like.

The invention discloses a quick panda progesterone concentration determination method. On the premise of no difference between detection results of urine samples, three hours for whole determination process of panda progesterone concentration is shortened to 1.5 hours by changing 2-hour incubation at conventional room temperature into 0.5-hour incubation at 37 DEG C, determination time is shortened by 50%, and precious time is earned for natural mating and artificial insemination in good time.

The invention discloses a reagent preparation technique which can fast test the blood ketone. The technique includes first assemble a level of metal nanometer particles on pre-processed electric pole with electrochemical deposit technique. And then fix the reaction reagent on the nanometer particle layer forming reaction layer. When blood ketone drop is dropt on the reaction layer, the basal material will reaction with the solution generate electric signals testable with electrochemistry bio sensor testing system outputting corresponding intensity signal.

In the production of hydrogen peroxide, a higher alcohol component in an organic solvent changes into a ketone body and increase in the ketone bodies reduces water content of a working solution and causes deterioration of catalytic activity. In addition, increase in the ketone bodies may obstruct stable and safe operation during the production of hydrogen peroxide due to decrease in the solubility of anthrahydroquinones, crystallization, precipitation, etc. The objective of the present invention is to provide a method for improving hydrogen peroxide production efficiency by regenerating an altered substance (ketone body) derived from a polar solvent in the working solution used for the production of hydrogen peroxide by the anthraquinone method to the original alcohol component. Hydrogen peroxide can be produced more efficiently by distilling off the organic solvent component including the ketone body from the working solution which has been used over time and hydrogenating the same under the presence of a metal catalyst to regenerate to the original alcohol component.

An apparatus 10 for predicting change in a physical index includes an acquisition unit 13, a setting unit 12, and a calculation unit 18. The acquisition unit 13 acquires the ketone body concentration excreted by a subject. The setting unit 12 sets a set time at a present time or a later time. The calculation unit 18 calculates a predicted value of change in the physical index based on the ketone body concentration and on the set time. The predicted value of change in the physical index is the change in body weight of the subject or in the weight of body fat when the designated time elapses.

Method of identification and quantitative analysis of aldehyde(s) and / or ketone(s) in a sample by mass spectrometry using stable isotope labeled internal standard is provided. Said internal standard is prepared by reaction of an authentic sample of said aldehyde(s) and / or ketone(s) with a stable isotope labeled reagent, and is added to a sample containing said aldehyde(s) and / or ketone(s). Said aldehyde(s) and / or ketone(s) in said sample is then quantitatively converted to a chemical compound of identical structure, except the stable isotope atoms, as that of said internal standard using a non-labeled reagent. Said sample is then extracted and the extract is analyzed by mass spectrometry. Identification and quantification of said aldehyde(s) and / or ketone(s) are made from a plot of ion ratio of said converted aldehyde and / or ketone to said internal standard versus aldehyde and / or ketone concentration.

Ketogenic compositions include a non-racemic mixture of beta-hydroxybutyrate salts and acid(s) enriched with the R-enantiomer. The compositions are enriched with the R-enantiomer to elevate ketone bodies and increase the rate at which ketosis is achieved yet contains an amount of the S-enantiomer to provide alternative benefits. Beta-hydroxybutyric acid is more rapidly absorbed and utilized by the body than salts or esters, enhances taste, and reduces the need to include citric acid or other edible acids. Beta-hydroxybutyrate salts are more slowly absorbed and utilized by the body and can provide one or more electrolytes. Compositions for increasing ketone body level in a subject may contain a dietetically or pharmaceutically acceptable carrier and a non-racemic mixture of R-beta-hydroxybutyrate and S-beta-hydroxybutyrate, wherein the non-racemic mixture of R-beta-hydroxybutyrate and S-beta-hydroxybutyrate contains from about 50.5% to 99.5% by enantiomeric equivalents of R-beta-hydroxybutyrate and from about 49.5% to about 0.5% by enantiomeric equivalents of S-beta-hydroxybutyrate.

The disclosed testing method for measuring the severity of an illness in real-time can assess the severity of an illness in more detail than the existing APACHE II and SOFA scores. Said method can accurately measure the amount of ATP in a sample and accurately and quickly deduce the "state of intracellular energy, which organisms need in order to live" from the amount of ATP, and thus can evaluate the severity of an illness. Furthermore, the ATP concentration is used as an index to re-evaluate the amount of lactic acid accumulated in the sample as a result of breakdowns in metabolic balance accompanying increasing disease severity (specifically, the lactic acid level (mM) is divided by the ATP concentration (mM)), thereby providing a novel biomarker, the ATP-Lactate Energy Risk Score (A-LES), that can assess the severity of an illness. Additionally, the ATP concentration is used as an index to re-evaluate the ketone body level in the sample (specifically, the ketone body level (mM) is divided by the ATP concentration (mM)), thereby providing a novel biomarker, the ATP-Ketone Energy Risk Score (A-KES), that can assess the severity of an illness.

The invention relates to a method for detecting aldehyde ketone concentration in the atmosphere through combination of DNPH-silica-gel adsorption small columns and a HPLC-UV. The method comprises the following steps: (1) a sampling efficiency experiment: connecting two DNPH-silica-gel adsorption small columns in series, connecting the combined small columns with a sampling pump, and collecting an aldehyde ketone gas sample of which the concentration is known; (2) an atmosphere collection experiment: connecting a flowmeter, a potassium iodide copper pipe, the DNPH-silica-gel adsorption small columns and the sampling pump in sequence, so as to collect an aldehyde ketone gas sample in the ambient air; (3) sample treatment and analysis: slowly flushing the collected samples with acetonitrile, quantifying with a volumetric flask, and then carrying out detection through the HPLC-UV. The method has the advantages that the sampling efficiency can be 99 percent or above, the replicate analysis standard deviation of experiment data is less than 5 percent, the detection limit is as low as 0.05 to 0.15 microgram / m<3>, the detection accuracy is 3.01 to 9.65 percent, and the method is high in practicability.

Disclosed herein are “ketannabis” (or “ketonnabis”) compositions including a combination of: (1) tetrahydrocannabinol (THC); (2) a ketone body component such as beta-hydroxybutyrate (BHB) and / or acetoacetate; and (3) a dietetically or pharmaceutically acceptable carrier. Also disclosed herein are methods of using such ketannabis compositions for producing desired physiological effects. The ketannabis compositions beneficially enhance the euphoric effects of THC without aggravating common side effects or even acting to reduce common side effects such as anxiety, disruption of short-term memory, appetite increases, heart rate increases, and blood pressure changes.

Devices, patch sensors, and methods for detecting a ketone body are disclosed. An exemplary device includes a collection apparatus for collecting a sample amount of interstitial fluid and a ketone body indicator having an initial negative state and having a positive state when at least a threshold value of the ketone body is collected in the sample amount.

The invention belongs to the field of biotechnology, and particularly relates to an oligomer of (R)-3-hydroxybutyric acid and a preparation method and application of the oligomer. According to the oligomer represented by a formula I (please see the specification for the formula), n=3-10, and preferably n=3-8; and R can be H, a linear alkyl group such as methyl and ethyl, a branched alkyl group such as n-propyl and isopropyl, an aralkyl group such as benzyl and phenethyl or a metal ion such as Na, K, Ca and Mg, and more preferably ethyl. The oligomer of (R)-3-hydroxybutyric acid has the effectof increasing the level of ketone bodies in organisms, can prolong the action time and play a sustained release effect, can reduce the risks of acidosis and metal ion overload, and has the characteristics of high safety, small side effects and long action time.